Loading...
Market
GSK mRNA flu vaccine market share by end of 2025?
2
Resolution / Starting Odds
<10% • 25%
10-20% • 25%
20-30% • 25%
>30% • 25%
Market research reports and industry analysis
Story
GSK Acquires Full Rights to Develop mRNA Flu and COVID-19 Vaccines from CureVac for €1.4 Billion
Jul 3, 2024, 07:27 AM
GSK and CureVac have restructured their collaboration into a new licensing agreement. As part of the deal, GSK will acquire full rights to develop and manufacture mRNA flu and COVID-19 shots from CureVac. The agreement includes a payment of up to €1.4 billion.
View original story
Similar markets
Under $500 million • 33%
$500 million - $1 billion • 33%
Over $1 billion • 33%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
Positive • 33%
Neutral • 33%
Negative • 33%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Under $1 billion • 33%
$1 billion - $2 billion • 33%
Over $2 billion • 33%
Pfizer • 25%
GlaxoSmithKline • 25%
Moderna • 25%
Other • 25%
Less than 25% • 25%
25-50% • 25%
50-75% • 25%
More than 75% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
